N-acetylsulfapyridine (NAS) is a prodrug of sulfapyridine, an antibacterial agent used to treat inflammatory bowel disease (IBD). It is synthesized by acetylation of sulfapyridine. NAS is poorly absorbed orally and undergoes hydrolysis to sulfapyridine in the gut. Sulfapyridine has anti-inflammatory effects, but it is poorly absorbed and has significant adverse effects. NAS was developed to improve the bioavailability and reduce the side effects of sulfapyridine. It is studied for its potential therapeutic benefits in IBD, including ulcerative colitis and Crohn's disease. NAS is also investigated for its potential use in other inflammatory conditions, such as rheumatoid arthritis. However, due to the emergence of newer and safer treatments for IBD, the use of NAS has declined.'
acetylsulfapyridine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 58638 |
| CHEMBL ID | 1507581 |
| CHEBI ID | 165191 |
| SCHEMBL ID | 547543 |
| MeSH ID | M0046873 |
| Synonym |
|---|
| HMS2625K12 |
| OPREA1_445484 |
| acetylsulfapyridine |
| n-acetylsulfapyridine |
| 2-(n4-acetylsulfanilamido)pyridine |
| ccris 6818 |
| brn 0269306 |
| 2-(n4-acetylsulfanilamide)pyridine |
| 4'-(2-pyridylsulphamoyl)acetanilide |
| n(sup 4)-acetylsulfapyridine |
| einecs 242-802-5 |
| n-(4-((2-pyridinylamino)sulfonyl)phenyl)acetamide |
| acetamide, n-(4-((2-pyridinylamino)sulfonyl)phenyl)- |
| acetanilide, 4'-(2-pyridylsulfamoyl)- |
| smr000272989 |
| MLS000713508 |
| STK086492 |
| n-[4-(pyridin-2-ylsulfamoyl)phenyl]acetamide |
| OPREA1_841941 |
| n4-acetylsulfapyridine |
| 19077-98-6 |
| n-[4-(pyridin-2-ylsulamoyl)phenyl]acetamide |
| CHEBI:165191 |
| AKOS000673234 |
| FT-0661371 |
| NCGC00245166-01 |
| n-{4-[(pyridin-2-yl)sulfamoyl]phenyl}acetamide |
| unii-3cm4b5mzjp |
| acetylsulphapyridine |
| 5-22-08-00426 (beilstein handbook reference) |
| 3cm4b5mzjp , |
| n-acetyl sulfapyridine |
| n4-acetylsulfapyridine-d4 |
| acetamide, n-[4-[(2-pyridinylamino)sulfonyl]phenyl]- |
| CYLYVXPHAQLXFG-UHFFFAOYSA-N |
| n-[4-[(2-pyridinylamino)sulfonyl]phenyl]-acetamide |
| CHEMBL1507581 |
| SCHEMBL547543 |
| n-(4-(n-(pyridin-2-yl)sulfamoyl)phenyl)acetamide |
| DTXSID5066453 |
| AE-842/30367013 |
| n-{4-[(2-pyridinylamino)sulfonyl]phenyl}acetamide |
| n-[4-(2-pyridylsulfamoyl)phenyl]acetamide |
| n4-acetylsulfapyridine, analytical standard |
| J-012323 |
| Q27257040 |
| n~1~-{4-[(2-pyridylamino)sulfonyl]phenyl}acetamide |
| Z45654196 |
| PD127982 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Coadministration of zileuton did not significantly affect the area under the plasma concentration-time curve, the maximum (Cmax) or minimum (Cmin) plasma concentration and the time to Cmax of SASP, SP or ASP." | ( The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Awni, WM; Braeckman, RA; Dubé, LM; Granneman, GR; Locke, CS, 1995) | 0.49 |
| " We investigated the effects of genetic polymorphism of NAT2 on pharmacokinetic profiles of SASP and its two metabolites, sulfapyridine (SP) and N-acetylsufapyridine (AcSP)." | ( Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Cao, XM; Li, JH; Liu, CG; Ma, JJ; Sun, SL; Yao, X, 2009) | 0.35 |
| " After taking 1000mg SASP tablets, the plasma concentrations of SASP, SP and AcSP were measured with HPLC method and pharmacokinetic parameters were calculated by using the computing program 3P97." | ( Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Cao, XM; Li, JH; Liu, CG; Ma, JJ; Sun, SL; Yao, X, 2009) | 0.35 |
| "The AUC(0)(-)(72) and Cmax of SP in m/m subjects were significantly higher than those in w/m and w/w subjects, with the values of 172." | ( Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. Cao, XM; Li, JH; Liu, CG; Ma, JJ; Sun, SL; Yao, X, 2009) | 0.35 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "In two bioavailability studies performed under comparable conditions with 24 healthy subjects of both genders equally distributed, plasma levels of SP and acetylsulfapyridine (Ac-SP) were determined after oral intake of enteric coated formulations of sulfasalazine (500 mg and 1,000 mg, respectively)." | ( Phenotyping with sulfasalazine - time dependence and relation to NAT2 pharmacogenetics. Anschütz, M; Blume, HH; Hippius, M; Kuhn, UD; Schmücker, K; Schug, BS, 2010) | 0.36 |
| Class | Description |
|---|---|
| sulfonamide | An amide of a sulfonic acid RS(=O)2NR'2. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 4.4668 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 28.1838 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 4 (20.00) | 18.2507 |
| 2000's | 4 (20.00) | 29.6817 |
| 2010's | 6 (30.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.27) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (15.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 4 (20.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (65.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||